EUCTR2018-003307-19-IT进行中（未招募）1 期
A double-blind, randomized, vehicle-controlled clinical multi-center study to evaluate the efficacy and safety of N-Acetyl-GED-0507-34-LEVO gel, 2 and 5%, applied once daily for 12 weeks in patients with facial acne vulgaris - GEDACNE
PPM SERVICES S.A.0 个研究点目标入组 450 人开始时间: 2020年11月10日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 450
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Informed consent obtained**Written informed consent, before any study related procedure, personally signed and dated by the patient if the patient is = 18 years old, or signed and dated by the parent(s) or the legal guardian if the patient is = 12 to < 18 years old. An additional informed assent form must be signed by the patient if = 12 to <18 years old to confirm his willingness to participate in the study. If the patient becomes 8 years of age during the study, the patient must provide written informed consentat that time to continue study participation 2. Male and female patients aged = 12 to = 30 years old inclusive;3. Diagnosis: Patients with facial acne vulgaris with an investigator's global assessment (IGA) score of 3–4 at screening and baseline visits; 4. Inflammatory lesions: Patients with = 20 and =100 inflammatory lesions (papules and pustules) on the face (excluding the nose) and = 1 nodules; 5. Non-inflammatory lesions: Patients with = 20 and = 100 non-inflammatory lesions (open and closed comedones) on the face (excluding the nose); 6. Full comprehension: Patient and parent(s)/guardian for <18 years old patient's ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to cooperate with the investigator and to comply with the requirements of the entire study; 7. Contraception and fertility: Women of childbearing potential must be using an effective contraception method during the entire duration of the study. Stable treatment period is required for the following reliable methods of contraception: •Hormonal oral, implantable, transdermal, or injectable contraceptives must be stable for at least 6 months before the screening visit • A nonhormonal intrauterine device (IUD) must be started at least 2 months
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 225
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1Pats with spontaneously improving or rapidly deteriorating acne within at least 3 months before study baseline. Pats who have a known history of acne unresponsive to topical and/or oral treatments. In particular subjects with history of persistent acne (a continuation of the
- •disease from adolescence into adulthood) and subjects with history of relapsing acne. Patients with generalized or localized acne forms other than acne vulgaris, e.g., acne conglobata, acne fulminans, acne rosacea,secondary acne (chloracne, drug-induced acne, etc), nodule-cystic acne,acne tarda or acne requiring systemic treatment. 2.Pats. who have abeard or who intend to grow a beard and/or to perform a facial tattoo during the study. Pat. has facial hair or facial tattoos that couldinterfere with the study assessments in the opinion of the investigator.3Pats with other active skin diseases or active skin infections in the facial region(bacterial, fungal, or viral) or any other facial disease or condition thatmight interfere with the evaluation of acne or place the pat. atunacceptable risk.4. Known or suspected hypersensitivity to or inactive ingredient in the study products. Pats with a history of an allergic reaction or significant sensitivity to the formulations' ingredients 5. Patients using, will use during the study, or discontinued less than 4 weeks before study baseline, prescribed or over-the-counter topical therapies for the treatment of acne including but not limited to: corticosteroids, antibiotics, azelaic acid, benzoyl peroxide salicylates, a- hydroxy/glycolic acid, any other topical cosmetic therapy for acne and retinoids on the face. 6. Pats using, will use during the study, or discontinued less than 4 weeks before study baseline, facial application of products containing glycolic or other acids, masks, washes or soaps containing benzoyl peroxide or salicylic acid, non-mild cleansers ormoisturizers containing retinol, salicylic or alpha- or beta-hydroxy acids,facial procedures such as chemical peel, laser treatment, photodynamic therapy, acne surgery, cryodestruction or chemodestruction, x-ray therapy, intralesional steroids, dermabrasion, or depilation (except eyebrow shaping). 7. Patients using, will use during the study, or discontinued less than 12 weeks before study baseline, phototherapy for the treatment of acne including but not limited to: UV-A, UV-B, heliotherapy. Patients who have the need or plan to be exposed to artificial tanning devices or excessive sunlight during the study. 8. Patients using, will use during the study, or discontinued less than12weeks before study baseline, systemic therapies for the treatment of acne including but not limited to: antibiotics, isotretinoin. Other systemictherapy which, in the opinion of the investigator, could affect thepatient's acne . 9. Known systemicdiseases that can lead to acneiform eruptions:10. Participation in the evaluation of any investigational product or device within 30 days before study baseline 11. Patient with underlying uncontrolled or unstable conditions (including, but not limited to metabolic, hematologic, renal, hepatic, pulmonary, neurologic,
- •endocrine, cardiac, infectious or gastrointestinal) which in the opinion of the investigator could significantly compromise the patient's safety and/or place the patient at an unacceptable risk. Any condition which in
- •the investigator's opinion would make it unsafe for the patient toparticipate in the study 12. History of alcohol or oth
研究者
相似试验
进行中（未招募）
1 期
A double-blind, randomized, vehicle-controlled clinical multi-center study to evaluate the efficacy and safety of N-Acetyl-GED-0507-34-LEVO gel, 2 and 5%, applied once daily for 12 weeks in patients with facial acne vulgarisfacial acne vulgarisMedDRA version: 20.0Level: PTClassification code 10000496Term: AcneSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2018-003307-19-DEPPM SERVICES S.A.450
进行中（未招募）
1 期
A double-blind, randomized, vehicle-controlled clinical multi-center study to evaluate the efficacy and safety of N-Acetyl-GED-0507-34-LEVO gel, 2 and 5%, applied once daily for 12 weeks in patients with facial acne vulgarisfacial acne vulgarisMedDRA version: 20.0Level: PTClassification code 10000496Term: AcneSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2018-003307-19-PLPPM SERVICES S.A.450
已完成
不适用
A double blind, randomised, vehicle-controlled, safety and tolerance study of topical PSK 3841 solution at 5% administered twice daily over four weeks to healthy Caucasian males with androgenetic alopeciaAndrogenetic alopecia.Skin and Connective Tissue DiseasesAndrogenetic alopeciaISRCTN49873657ProStrakan Pharmaceuticals (France)60
进行中（未招募）
1 期
A randomized, double-blind, vehicle controlled, single center, intra-individual comparative study of the efficacy and safety of diclofenac sodium 1 mg/g (0.1%) gel in subjects with painful UV-induced erythema - Diclofenac sodium 1 mg/g (0.1%) gelEUCTR2006-004524-36-FRovartis Consumer Health SA
进行中（未招募）
不适用
A randomized, double-blind, vehicle-controlled, half-side comparison, monocenter, clinical study evaluating the efficacy and safety of a herbal dermatitis ointment for the treatment of mild to moderate atopic dermatitisatopic dermatitisEUCTR2004-002594-23-DEWeber & Weber GmbH & Co.KG